Systemic Anaplastic Large Cell Lymphoma News and Research

RSS
Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Systemic ALCL is a type of T-cell non-Hodgkin lymphoma that expresses the CD30 antigen. Although standard front-line combination chemotherapy regimens used to treat systemic ALCL often result in long-term remissions and cures, there are limited therapeutic options and a strong unmet medical need for patients with relapsed or refractory disease. SGN-35 has received orphan drug designation for ALCL from both the FDA and the European Medicines Agency.
FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatment

FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatment

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

SGEN, Abbott enter collaboration agreement for ADC products

SGEN, Abbott enter collaboration agreement for ADC products

Millennium, SGEN expand ADC collaboration

Millennium, SGEN expand ADC collaboration

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics enters ADC collaboration agreement with Pfizer

Seattle Genetics enters ADC collaboration agreement with Pfizer

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

USPTO issues patent related to Seattle Genetics' ADC technology

USPTO issues patent related to Seattle Genetics' ADC technology